Skip to main content

Anti-Rheumatic Rx

dementia,brain

Rheumatoid Arthritis, Dementia and Cognitive Dysfunction

Dec 02, 2021

Rheumatoid arthritis (RA) has been linked to a higher risk of dementia and cognitive dysfunction, but interestingly this association has diminished in the last few decades with aggressive DMARD and targeted therapies..



This makes sense when you see that dementia in RA is associated

Read Article
liver.jpg

Methotrexate and hepatic fibrosis: we must be doing something right

Dec 02, 2021

Methotrexate may be a rheumatologist’s best friend, but a key part of counselling any patient about its use has always been the risk of hepatotoxicity. Despite methotrexate’s near-ubiquitous use in rheumatology, and the consequent frequency of patient counselling about it, relatively little

Read Article
lung%2Cbright.jpg

Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles

Dec 01, 2021

Pulmonary complications in the setting of Still's disease (juvenile and adult) has seldom but consistently been reported, including reports of pneumonitis, pulmonary hypertension and a severe or fatal lung disease, often associated with hypersensitivity to anticytokine therapy. A multicenter

Read Article
Plaquenil.HCQ_.pills_.jpg (keep)

Prolonging the Controversy of Hydroxychloroquine

Nov 30, 2021

Since the start of the pandemic, hydroxychloroquine (HCQ) was forced into the limelight for the prevention/treatment of COVID-19. When it was found to be ineffective for COVID-19 and might cause potential harm, the drug came under closer scrutiny for its safety profile.

Read Article
Sle.vote_.criteria.png

DORIS - Defining Remission in Lupus

Nov 29, 2021

Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE.  A SLE Definitions Of Remission (DORIS)Task Force was convened in 2015 and first published their work in 2016. Now the 2021

Read Article
keystone

RheumNow Podcast - 60/40/20 Interview with Dr. Ed Keystone

Nov 26, 2021

Dr. Jack Cush interviews Professor Edward Keystone, MD (University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.


Read Article
rachel.tate

Safety of Psoriatic Biologics in Pregnancy

Nov 24, 2021

Little is known about the safety of newer biologic use during pregnancy, especially in patients who either conceive while on a biologic or must remain on a biologic during pregnancy (often the case with IBD and inflammatory arthritis). A report from ACR 2021 (Abstract 1713) examined the risk

Read Article
jon.kay

Does Control of Inflammation Lower Cancer Risk?

Nov 23, 2021

Dr. Jonathan Kay's provocative video addresses whether the increased cancer risk associated with tofacitinib (Tofa) seen in the Pfizer Oral Surveillance (1133) study represents a real increased risk, an increased risk relative to a decreased risk with TNF inhibitors (TNFi) or an actual decreased

Read Article
#ACR21 is complete--view all our RheumNow's coverage.https://t.co/wkZ66lcB44

Dr. John Cush @RheumNow( View Tweet )

Nov 23, 2021
phone.jpg

Improving Rheumatology Practice

Nov 22, 2021

How to best book patient appointments in rheumatology clinic? Should these be scheduled every 3 or 4 months regardless of patient status? Should they be scheduled by patient need or disease activity? 

Read Article
ICYMI: An Old Friend – Methotrexate in Psoriatic Arthritis Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, particularly in the care of peripheral arthritis such as PsA.https://t.co/kJdQ9Pd67v#ACR21 @_Castillo_Pedro https://t.co/lpvZJaPcYd
Dr. John Cush @RheumNow( View Tweet )
Nov 21, 2021
RheumNow Podcast square

RheumNow Podcast - Unwillingness to Change Therapy (11.19.21)

Nov 19, 2021

Surely you’ve seen this or been plagued by this patient, one that is not doing well, in need of a new regimen; you outline it, timeline it, define the side effects and send them off with a new prescription.. But you later find out they did not change, did not fill the prescription.  Why were

Read Article
Conway still

GLORIA Study - Is Prednisone Harmful in Elder RA?

Nov 17, 2021

The GLORIA study (ABST# 1678) was a pragmatic, blinded placebo-controlled randomized trial from Dr. Martin Boers and colleagues where they assessed whether prednisolone (vs. placebo) use would alter clinical outcomes over 2 years.



A total of 451 elder patients with established RA

Read Article
PSA2L.jpg

An Old Friend – Methotrexate in Psoriatic Arthritis

Nov 16, 2021

Methotrexate (MTX) remains one of our most used and reliable tools against a variety of rheumatic diseases, including PsA. When the time comes, as it often does, to escalate from a MTX-monotherapy approach, we have several options. In clinic, initiation of these other medications has often been

Read Article
RheumNow Podcast square

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

Nov 12, 2021

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Read Article
ACR Best

ACR21 Best Abstracts - Day 4

Nov 10, 2021

On the last day of ACR21 Annual Meeting, the RheumNow faculty selected these 15 as their favorite reports.

Read Article
EULAR19.abstract.jpg (keep)

ACR21 – Day 3 Report

Nov 09, 2021

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites: secukinumab efficacy in juvenile PsA; VEXAS - predicting poor outcomes; and the FDA Safety Update session.

Read Article
Thank you @AhmadSherbini for discussing his #ACR21 research on @RheumNow on Abs#1444 - Can we predict which patients are most likely to have nausea or alopecia intolerance to MTX?https://t.co/I5WmCECq7v
Nov 09, 2021
Racial disparities & Co-morbidities in PsA findings. Amongst important others, increased biologic use in Caucasians w/ PsA vs DMARDs in black PsA pts. View Abs 1780 for other relevant findings. #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/0uKsa8i0bG https://t.co/R9YkxYqXws
Dr. Rachel Tate @uptoTate( View Tweet )
Nov 09, 2021
Methotrexate did not improve Ustekinumab efficacy in tx of PsA ⭐️Addition of MTX did not improve dactylitis, enthesitis, skin, QoL or function #ACR21 #ACRBest @RheumNow Abs#L12https://t.co/6dxWPNskou https://t.co/BnzH8PfaMV
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
No benefit to using MTX in combination with ustekinumab in PsA. No difference in efficacy for arthritis, enthesitis, dactylitis, skin, QoL or function. Abstr#L12 #ACR21 @RheumNow https://t.co/iojKLqRb06
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
GLORIA study of adding prednisolone 5mg to DMARDs over 2 years for RA in those >65 years. Mean DAS 0.37 points lower, Sharp score 1.7 lower (are either of these clinically significant?). NNH 9.5. To me causing harm chasing statistical benefit Abstr#1678 #ACR21 @RheumNow #ACRBest https://t.co/KYk1II3J3w
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ
Richard Conway @RichardPAConway( View Tweet )
Nov 09, 2021
No significant difference in enthesitis activity in PsA pts taking csDMARD vs. TNFi vs. IL-17i ⭐️Age, duration of disease, physician global were main differences in TNFi and IL-17i vs. cDMARD ⭐️no specific clustering noted Abs#1782 #ACR21 @RheumNow https://t.co/AH33ZjHUa1 https://t.co/Gb2zKMBUqo
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 09, 2021
#ACR21 Abs#1677. Effects of bDMARD on Lipids: ⬆️ HDL from 62 -> 66 in 1yr (p=0.013) ❌ No signif change in LDL or LDL-C/HDL-C ratios @Rheumnow https://t.co/uMsXKwwqvW https://t.co/fhCbDoa3px
Nov 09, 2021
×